Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,025 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.
Coombes RC, Howell S, Lord SR, Kenny L, Mansi J, Mitri Z, Palmieri C, Chap LI, Richards P, Gradishar W, Sardesai S, Melear J, O'Shaughnessy J, Ward P, Chalasani P, Arkenau T, Baird RD, Jeselsohn R, Ali S, Clack G, Bahl A, McIntosh S, Krebs MG. Coombes RC, et al. Among authors: howell s. Nat Commun. 2023 Jul 24;14(1):4444. doi: 10.1038/s41467-023-40061-y. Nat Commun. 2023. PMID: 37488191 Free PMC article. Clinical Trial.
Breast cancer: current and future endocrine therapies.
Palmieri C, Patten DK, Januszewski A, Zucchini G, Howell SJ. Palmieri C, et al. Mol Cell Endocrinol. 2014 Jan 25;382(1):695-723. doi: 10.1016/j.mce.2013.08.001. Epub 2013 Aug 7. Mol Cell Endocrinol. 2014. PMID: 23933149 Review.
Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial.
Earl HM, Hiller L, Dunn JA, Blenkinsop C, Grybowicz L, Vallier AL, Abraham J, Thomas J, Provenzano E, Hughes-Davies L, Gounaris I, McAdam K, Chan S, Ahmad R, Hickish T, Houston S, Rea D, Bartlett J, Caldas C, Cameron DA, Hayward L; ARTemis Investigators. Earl HM, et al. Lancet Oncol. 2015 Jun;16(6):656-66. doi: 10.1016/S1470-2045(15)70137-3. Epub 2015 May 11. Lancet Oncol. 2015. PMID: 25975632 Free article. Clinical Trial.
Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer.
Palmieri C, Macpherson IR, Yan K, Ades F, Riddle P, Ahmed R, Owadally W, Stanley B, Shah D, Gojis O, Januszewski A, Lewanski C, Asher R, Lythgoe D, de Azambuja E, Beresford M, Howell SJ. Palmieri C, et al. Oncotarget. 2016 Mar 15;7(11):13209-20. doi: 10.18632/oncotarget.4801. Oncotarget. 2016. PMID: 26334099 Free PMC article.
A phase II trial of low-dose estradiol in postmenopausal women with advanced breast cancer and acquired resistance to aromatase inhibition.
Zucchini G, Armstrong AC, Wardley AM, Wilson G, Misra V, Seif M, Ryder WD, Cope J, Blowers E, Howell A, Palmieri C, Howell SJ. Zucchini G, et al. Among authors: howell sj, howell a. Eur J Cancer. 2015 Dec;51(18):2725-31. doi: 10.1016/j.ejca.2015.08.028. Epub 2015 Nov 18. Eur J Cancer. 2015. PMID: 26597446 Clinical Trial.
IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients.
Palmieri C, Stein RC, Liu X, Hudson E, Nicholas H, Sasano H, Guestini F, Holcombe C, Barrett S, Kenny L, Reed S, Lim A, Hayward L, Howell S, Coombes RC; IRIS trial participants. Palmieri C, et al. Among authors: howell s. Breast Cancer Res Treat. 2017 Sep;165(2):343-353. doi: 10.1007/s10549-017-4328-z. Epub 2017 Jun 13. Breast Cancer Res Treat. 2017. PMID: 28612226 Free PMC article.
Correction to: IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients.
Palmieri C, Stein RC, Liu X, Hudson E, Nicholas H, Sasano H, Guestini F, Holcombe C, Barrett S, Kenny L, Reed S, Lim A, Hayward L, Howell S, Charles Coombes R; IRIStrial participants. Palmieri C, et al. Among authors: howell s. Breast Cancer Res Treat. 2018 Jan;167(1):407. doi: 10.1007/s10549-017-4539-3. Breast Cancer Res Treat. 2018. PMID: 29071491 Free PMC article.
A phase IB and randomised phase IIA trial of CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases: CARBON trial results.
Winter M, Coleman R, Kendall J, Palmieri C, Twelves C, Howell S, MacPherson I, Wilson C, Purohit K, Gath J, Taylor C, Eastell R, Murden G, Brown SR, Rathbone E, Brown J. Winter M, et al. Among authors: howell s. J Bone Oncol. 2022 Jun 24;35:100442. doi: 10.1016/j.jbo.2022.100442. eCollection 2022 Aug. J Bone Oncol. 2022. PMID: 35800293 Free PMC article.
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, Hu X, Jhaveri K, Krivorotko P, Loibl S, Morales Murillo S, Okera M, Park YH, Sohn J, Toi M, Tokunaga E, Yousef S, Zhukova L, de Bruin EC, Grinsted L, Schiavon G, Foxley A, Rugo HS; CAPItello-291 Study Group. Turner NC, et al. Among authors: howell sj. N Engl J Med. 2023 Jun 1;388(22):2058-2070. doi: 10.1056/NEJMoa2214131. N Engl J Med. 2023. PMID: 37256976 Clinical Trial.
2,025 results